RxDoctor Payments Data

Lauren Hardy, PA

Physician Assistant · Sikeston, MONPI 1881009934

Payments from drug & device makers

$4,771in general payments, 2019–2025

Across 245 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$595
  • Amgen$573
  • AstraZeneca$450
  • Novo Nordisk$304
  • Otsuka America Pharmaceutical, Inc.$185
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,771 in reported general payments places this provider in the 90th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$575
Medicare patients
11
Services billed
11

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide39$41,189
OzempicSemaglutide19$16,234
RexultiBrexpiprazole11$15,429
JardianceEmpagliflozin23$14,027
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,581
TrulicityDulaglutide12$12,411
InvokanaCanagliflozin11$6,192
MyrbetriqMirabegron13$5,995
Dexlansoprazole DrDexlansoprazole15$2,226
Estradiol11$888
Cefdinir47$885
Rosuvastatin Calcium111$855
Eszopiclone25$747
Doxycycline Hyclate50$592
SynthroidLevothyroxine Sodium11$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$595$53,59951 claims
Novo NordiskOzempic$304$16,23419 claims
Otsuka America Pharmaceutical, Inc.Rexulti$185$15,42911 claims
Boehringer IngelheimJardiance$49$14,02723 claims
AstraZenecaBreztri Aerosphere$450$13,58121 claims
Johnson & JohnsonInvokana$123$6,19211 claims
AbbVieSynthroid$1,093$52811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Sikeston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →